Navigation Links
CpGenome™ Fast DNA Modification Kit from CHEMICON

ProductsCpGenome™ Fast DNA Modification Kit from CHEMICON
Company CHEMICON
Item CpGenome™ Fast DNA Modification Kit
Price $150.00
Description The CpGenome Fast DNA Modification Kit contains reagents required to perform a bisulfite modification on a DNA sample. In the bisulfite reaction, all unmethylated cytosines are deaminated and sulfonated, converting them to uracils, while 5-methylcytosines remain unaltered. Thus, the sequence of the treated DNA will differ depending on whether the DNA is originally methylated or unmethylated. Also, the initially complementary DNA strands will no longer be complementary after cytosine conversion. Primers for use in MSP can be designed to specifically amplify either a bisulfite-sensitive, unmethylated strand or a bisulfite-resistant, methylated strand, based upon these chemically-induced differences. • The PCR primers are designed to specifically amplify the promoter regions of the gene of interest. If the sample DNA was originally unmethylated, an MSP reaction product will be detectable when using the primer set (labeled as 'U') designed to be complementary to the unmethylated bisulfite converted DNA sequence. No product will be generated using a primer set (labeled as 'M') designed to be complementary to the derivative methylated DNA sequence. Conversely, an MSP product will be generated only using the M primer set if the sample was originally methylated, and the U primers will not amplify such a template.

  • Components: DNA Modification Reagent 6 g
    Binding Buffer 20 mL
    Wash Buffer* 12 mL
    Elution Buffer 1.5 mL
    DNA Modification Columns 25
Info CHEMICONCHEMICON
CHEMICON International, Inc.
28820 Single Oak Drive
Temecula, CA 92590
Customer Service: 800-437-7500
Tech Support: 800-437-7500
Fax Number: 800-437-7502
Web Site: http://www.chemicon.com
NOTE: Price information is approximate list price and actual prices may vary.

Related biology products :

1. CpGenome™ Universal DNA Modification Kit from Upstate
2. Nutrient Mixture F-12 Ham, Coons Modification (Hams F-12 Coons) from Sigma-Aldrich
3. Antibody Modification Services from Genescript
4. GIBCO Improved MEM Zn++ Option (Richters Modification) liquid from Invitrogen
5. EcoR I/Hind III End Modification Kit from Novagen
6. GIBCO BGJb Medium (Fitton-Jackson Modification) (1X) liquid from Invitrogen
7. GIBCO F-12K Nutrient Mixture Kaighns Modification (1X) liquid from Invitrogen
8. F-12K Nutrient Mixture Kaighns Modification (1x) liquid from Invitrogen
9. ES Cell Characterization Kit from CHEMICON
10. In Vitro Osteogenesis Assay Kit from CHEMICON
11. Human / Mouse / Rat Blood Vessels (CD31 / Von Willebrand Factor (vWF)) IHC staining Kit from CHEMICON
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2Alberta companies delivering new products to the health & medical marketplace 2